Quarterly Result12 Aug 2026, 06:30 pm
Suraksha Diagnostic Q1 FY27 PAT Up 40% to ₹128M
AI Summary
Suraksha Diagnostic Limited reported strong unaudited financial results for Q1 FY27, with Profit After Tax (PAT) growing 40% year-on-year to ₹128 million. Total income increased by 21% to ₹887 million, and EBITDA grew by 28% to ₹315 million, with an improved EBITDA margin of 36.0%. The company saw healthy growth in patient and test volumes, alongside increased realization per test and patient. Expansion efforts included commissioning one hub and three spoke centers. Suraksha Genomics also demonstrated significant growth, with revenue up 136% YoY.
Key Highlights
- PAT surged 40% YoY to ₹128 million in Q1 FY27.
- Total income rose 21% YoY to ₹887 million.
- EBITDA grew 28% YoY to ₹315 million.
- EBITDA margin improved to 36.0% from 34.0%.
- Suraksha Genomics revenue increased by 136% YoY.
Price Impact
More from SURAKSHA